Content
AI-Powered Drug Discovery Stocks Index Up 9% In February; Remains Down 8% YTD
Article By:
Lorimer Wilson
Read
Monday, March 4, 2024 12:41 AM EDT
Grand View Research says the global "AI in drug discovery" market should expand at a CAGR of 30% between now, and 2030 which Morgan Stanley believes will lead to 50 novel therapies over the next decade, with annual sales in excess of $50 billion.
Week In Review: Mabwell Sells Ex-China Rights To Rare Disease Therapy In $412 Million Deal
Article By:
ChinaBio® Today
Read
Saturday, March 2, 2024 2:00 PM EDT
Mabwell, a Shanghai-San Diego biotech, sold ex-China rights for 9MW3011 to Disc Medicine of Watertown, MA in a deal worth up to $412 million. Meanwhile, AstraZeneca has returned most of the global rights for Roxadustat to FibroGen.
Micro Marvel - Coya Therapeutics
Article By:
Jim Van Meerten
Read
Thursday, February 29, 2024 4:40 PM EDT
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs).
In this article: COYA
ADC Therapeutics - Time For A Turn-Around?
Article By:
Jim Van Meerten
Read
Tuesday, February 27, 2024 5:15 AM EDT
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates for patients suffering from hematological malignancies and solid tumors.
In this article: ADCT
Vertex Pharmaceuticals (VRTX) Should Remain Supported
Article By:
Elliottwave Forecast
Read
Tuesday, February 27, 2024 5:11 AM EDT
Vertex Pharmaceuticals Incorporated (VRTX), is a biotechnology company. It engages in developing & commercializing therapies for treating cystic fibrosis (CF).
In this article: VRTX
Lottery Preference And Biotech Stocks: Trust The Financials, Not The Science
Article By:
Alpha Architect
Read
Sunday, February 25, 2024 7:00 AM EDT
Making a bet on biotech/pharma firms that have not yet achieved significant revenue is the equivalent of buying a lottery ticket—with the same poor risk/return relationship.
Week In Review: AlphaGen And ArtBio Form China-US Radioligand Partnership
Article By:
ChinaBio® Today
Read
Saturday, February 24, 2024 2:20 PM EDT
Shanghai AlphaGen Therapeutics and ArtBio forged a far-reaching agreement to expand ArtBio’s market and develop new radioligand therapies. Additionally, Biocytogen Pharma signed an antibody evaluation/option agreement with Gilead Sciences.
MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential
Article By:
Vision And Value
Read
Thursday, February 22, 2024 6:15 AM EDT
MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months.
Zymeworks - Analysts Project A Big Turnaround
Article By:
Jim Van Meerten
Read
Tuesday, February 20, 2024 1:38 PM EDT
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer.
In this article: ZYME
AI-Powered Drug Discovery Stocks Index Up 18% Last Week, Led By BioXcel Therapeutics
Article By:
Lorimer Wilson
Read
Monday, February 19, 2024 12:05 AM EDT
The AI-powered drug discovery market is projected to grow at a 30% CAGR between now and 2030, with annual sales in excess of $50 billion anticipated. An AI drug discovery revolution is underway.
Psychedelic Stocks Index Popped 8% Last Week, Led By Incannex
Article By:
Lorimer Wilson
Read
Sunday, February 18, 2024 6:14 PM EDT
IXHL 's increase was based on the successful completion of an Investigational New Drug meeting with the FDA regarding the development of CannQuit-N for tobacco smoking cessation and relapse control.
Week In Review: LianBio To Close Operations; Will Pay $528 Million To Shareholders
Article By:
ChinaBio® Today
Read
Saturday, February 17, 2024 2:20 PM EDT
LianBio, a Princeton-Shanghai biotech, has decided to call it quits. LianBio plans to stop all of its operations by the end of 2024, and it will distribute a $4.80 dividend/share ($528 million) to its shareholders.
Chart Of The Day: Ironwood Pharma - Gastrointestinal Products
Article By:
Jim Van Meerten
Read
Tuesday, February 13, 2024 12:06 PM EDT
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products.
In this article: IRWD
Micro Marvel - Y-Mabs Therapeutics
Article By:
Jim Van Meerten
Read
Tuesday, February 13, 2024 5:30 AM EDT
Wall Street projected revenue will grow 26.00% this year and another 18.80% next year. Earnings are estimated to increase 68.90% this year but decrease 8.80% next year.
In this article: YMAB